Is MOLECULAR PARTNERS AG (MOLN) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 1.3% / 30% | 79.8% / 30% | 1.4% / 30% | 68.09% / 5% | ✗ NOT HALAL |
| DJIM | 1.3% / 33% | 79.8% / 33% | 1.4% / 33% | 68.09% / 5% | ✗ NOT HALAL |
| MSCI | 1.5% / 33% | 94.3% / 33% | 1.6% / 33% | 68.09% / 5% | ✗ NOT HALAL |
| S&P | 1.3% / 33% | 79.8% / 33% | 1.4% / 33% | 68.09% / 5% | ✗ NOT HALAL |
| FTSE | 1.5% / 33% | 94.3% / 33% | 1.6% / 50% | 68.09% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -55.5% | |
| Return on Assets (ROA) | -26.6% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$51M |
| Free Cash Flow | -$52M |
| Total Debt | $4M |
| Debt-to-Equity | 4.5 |
| Current Ratio | 8.8 |
| Total Assets | $102M |
Price & Trading
| Last Close | $4.30 |
| 50-Day MA | $4.57 |
| 200-Day MA | $4.06 |
| Avg Volume | 4K |
| Beta | 0.6 |
|
52-Week Range
$3.36
| |
About MOLECULAR PARTNERS AG (MOLN)
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in Phase 1 clinical trial to treat SCLC and neuroendocrine tumors. It also researches for Switch-DARPin T cell engager to treat CD3 x costim x; and MP0726, a Radio-DARPin Therapy to treat ovarian cancer and other MSLNexpressing cancers. In addition, the company develops MP0621, a Switch-DARPin candidate targeting CD16a, c-KIT, and CD47 as conditioning for hematopoietic stem cell transplantation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics and an additional six targeted alpha therapeutics candidates and Eckert & Ziegler SE to develop Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is MOLECULAR PARTNERS AG (MOLN) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), MOLECULAR PARTNERS AG is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is MOLECULAR PARTNERS AG's debt ratio?
MOLECULAR PARTNERS AG's debt ratio is 1.3% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 1.5%.
What are MOLECULAR PARTNERS AG's key financial metrics?
MOLECULAR PARTNERS AG has a market capitalization of $152M. Return on equity stands at -55.5%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.